Nav: Home

Big Pharma playing system to secure lucrative funding deals in Central Europe

January 11, 2018

New research, from an international group of health policy experts led by the University of Bath (UK), reports a mixed picture of transparency in public decisions-making around new medicine approvals in Poland, one of Europe's largest pharmaceutical markets.

Despite a troubled relationship with the European Commission, Poland has been hailed as a leader in modernising its assessment systems in establishing whether new drugs represent good value for money and merit significant public investment.

Drawing on comprehensive analysis of over 330 scientific drug assessments, the new findings suggest that the Polish Agency for Health Technology Assessment has reached the 'gold' transparency standard set by the National Institute for Health and Care Excellence (NICE) in England.

Surprisingly, the Polish Agency has even exceeded NICE in certain ways, such as providing details of the timing of assessment processes.

But, this is not a complete success story as there are still areas in which the Polish Agency significantly lags behind NICE. The research finds that scientific assessment reports include a high amount of redacted - or blacked out - information on drug prices, which prevents proper public scrutiny of decisions with huge financial consequences.

In addition, the Agency lacks transparency in disclosing potential conflicts of interest of its experts with multinational pharmaceutical giants. It is often unclear how many experts had financial ties to the industry, what their nature was and whether they were appropriately addressed.

The finding is supported by another piece of research, published last month, by the same research group. Based on over 100 interviews and thorough analysis of key policy documents, the study authors identify a 'Fire Exit' syndrome, where low-earning civil servants leave public organisations to take up highly paid jobs in the pharmaceutical sector. It also finds a pattern of Big Pharma co-opting medical experts working in an underfunded public healthcare sector using various incentives such as research funding.

The Polish Agency therefore struggles to access expertise which may not be perceived as biased by corporate interests. To make things worse, the Agency is exposed to strong pressure by patient organisations frequently reliant on pharmaceutical funding, in the absence of appropriate state grants.

Despite regulations being in place to govern conflicts of interest in the Polish context, this suggests these may in fact be counterproductive in that they could encourage attempts at establishing informal access to decision makers. Against a backdrop of widespread acceptance of industry influence on healthcare, it suggests health professionals would benefit from greater education about awareness of conflicts of interests, including at medical schools.

Lead author, Dr Piotr Ozieranski from the Department of Social & Policy Sciences, explains: "Our research suggests that despite the significant progress made in recent years, the assessment of medical technologies in Poland still has some way to go. Achieving full transparency regarding the nature and extent of potential conflicts of interests of medical experts is a key way of reassuring us, as members of the public, that decisions reached on funding of new drugs are based exclusively on the best possible independent, scientific evidence.

"This is important as in Poland both doctors and patients are exposed to powerful mechanisms of influence deployed by Big Pharma. Increased transparency is an important step in mitigating any undue influence.

"These findings suggest that more must be done to protect public health in Poland by being more open and transparent about potential conflicts of interest which could include through new education initiatives at medical schools."

The latest research builds on the previous work by showing how big pharma lobbies in Poland and in the West. It was funded via grants from the Department of Sociology and St Edmund's College, University of Cambridge.
-end-


University of Bath

Related Health Articles:

Health records pin broad set of health risks on genetic premutation
Researchers from the University of Wisconsin-Madison and Marshfield Clinic have found that there may be a much broader health risk to carriers of the FMR1 premutation, with potentially dozens of clinical conditions that can be ascribed directly to carrying it.
Attitudes about health affect how older adults engage with negative health news
To get older adults to pay attention to important health information, preface it with the good news about their health.
Geographic and health system correlates of interprofessional oral health practice
In the current issue of Family Medicine and Community Health (Volume 6, Number 2, 2018, pp.
Bloomberg era's emphasis on 'health in all policies' improved New Yorkers' heart health
From 2002 to 2013, New York City implemented a series of policies prioritizing the public's health in areas beyond traditional healthcare policies and illustrated the potential to reduce cardiovascular disease risk.
Youth consider mobile health units a safe place for sexual health services
Mobile health units bring important medical services to communities across the country.
More Health News and Health Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...